A Phase 3 interventional study of TX05 (trastuzumab) and Herceptin® in Breast Cancer, Breast Neoplasms and HER2-positive Breast Cancer, sponsored by Tanvex BioPharma USA, Inc.. Completed at 146 sites in 10 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-14.
Sponsored by Tanvex BioPharma USA, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 374 studies testing trastuzumab in Breast Neoplasms — 57 open to participants now, 86 under way, 5 of them phase 3. Trastuzumab · Breast Neoplasms.
Among the 374 studies testing trastuzumab in Breast Neoplasms, this one is the 23rd largest by enrollment of the 366 interventional ones that give a count, is one of 8 that started in 2018, is one of 60 in phase 3, and was the 263rd registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →57 of the 374 studies testing trastuzumab in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
SWOG Cancer Research Network · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 18+ · Women only
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–90
Shanghai Jiao Tong University School of Medicine · Sites in China
Ages 18–70 · Women only
Institut Curie · Sites in France
Ages 18+
By country, each count listing its studies:
Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, trastuzumab is the treatment under test here. Read study by study →
374 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 51 · Phase 2 270 · Phase 3 61 · Phase 4 7
First in 1998; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 809 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 61 across the 366 interventional studies. Of the 235 that completed or were terminated, 128 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
73 of 374 have an industry lead sponsor. The 10 most frequent:
Tanvex BioPharma USA, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Tanvex BioPharma USA, Inc. has 2 studies filed under Breast Neoplasms — fewer than ten, so there is no comparison to draw.
22 of the studies testing trastuzumab in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06035679Youzhi ZhuPyrotinib Combined With Trastuzumab and Chemotherapy Neoadjuvant Therapy for HER2-positive Breast Cancer | 2026-11-30 |
| NCT05891561Shanghai Jiao Tong University School of MedicineShort-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer | 2026-12 |
| NCT04886531Ruth O'ReganTrial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers | 2026-12-22 |
| NCT07095023Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNeoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer | 2026-12-30 |
| NCT07635342Hebei Medical University Fourth HospitalPyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer | 2026-12-31 |
Add all 22 to your calendar (.ics) → With an account.
Among the 374 studies testing trastuzumab in Breast Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase III, double-blind, randomized, multicenter study to compare the efficacy and to evaluate the safety and immunogenicity of TX05 (trastuzumab) with Herceptin® in subjects with HER2 positive early breast cancer.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
• Intravenous (IV) epirubicin, 75 mg/m\^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles Followed by: • IV TX05 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles
Biological: TX05 (trastuzumab) · Drug: Paclitaxel · Drug: Epirubicin · Drug: Cyclophosphamide
• Intravenous (IV) epirubicin, 75 mg/m\^2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles Followed by: • IV Herceptin 8 mg/kg loading dose then 6 mg/kg and paclitaxel 175 mg/m2 every 3 weeks for 4 cycles
Biological: Herceptin® · Drug: Paclitaxel · Drug: Epirubicin · Drug: Cyclophosphamide
8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
8 mg/kg, 90 min IV infusion (Cycle 5), followed by 6 mg/kg, 60 min IV infusion (Cycles 6 - 8)
175 mg/m\^2, 60 min IV infusion, every 3 weeks (Cycles 5-8)
Also known as: Ribotax
75 mg/m\^2, IV bolus infusion, every 3 weeks (Cycles 1-4)
600 mg/m\^2, 30 min IV infusion, every 3 weeks (Cycles 1-4)
Proportion of Subjects in Each Treatment Arm Who Achieve Pathologic Complete Response (pCR)
Pathologic complete response was determined by central review and defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled lymph nodes following neoadjuvant systemic therapy (ypT0/Tis ypN0).
Time frame: 3-7 weeks following last dose of study treatment
Objective Response Rate (ORR)
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (ORR) = CR + PR.
Time frame: End of Treatment (Week 24) or Early Termination Visit
A total of 809 subjects were randomized to the study. Of these, 806 subjects initiated protocol treatment.
| Milestone | TX05 (Trastuzumab) | Herceptin® |
|---|---|---|
| Started | 404 | 405 |
| Subjects treated | 401 | 405 |
| Subjects receiving tx05 or herceptin | 394 | 400 |
| Completed | 393 | 393 |
| Not completed | 11 | 12 |
| Withdrew: Subjects randomized that did not treat | 3 | 0 |
| Withdrew: Subjects who randomized and treated but drop prior to cycle 5 | 7 | 5 |
| Withdrew: Discontinued treatment after cycle 5 due to adverse event | 0 | 1 |
| Withdrew: Discontinued treatment after cycle 5 due to death | 0 | 1 |
| Withdrew: Discontinued treatment after cycle 5 due to consent withdrawn | 0 | 2 |
| Withdrew: Discontinued treatment after cycle 5 due to covid-19 | 0 | 1 |
| Withdrew: Discontinued treatment after cycle 5 due to other (subject decision) | 1 | 2 |
Pathologic complete response was determined by central review and defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled lymph nodes following neoadjuvant systemic therapy (ypT0/Tis ypN0).
| participants | TX05 (Trastuzumab) | Herceptin® |
|---|---|---|
| Subjects who do not Meet pCR Criteria | 172 | 185 |
| Subjects Meeting pCR Criteria | 164 | 153 |
Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Objective Response (ORR) = CR + PR.
| Participants | TX05 (Trastuzumab) | Herceptin® |
|---|---|---|
| Objective Response Rate (ORR) | 332 | 340 |
Collected over Serious Adverse Events were recorded from Screening, while Adverse Events were recorded from Day 1 (Week 0) of Cycle 1 of study treatment through End of Treatment (Week 24).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TX05 (Trastuzumab) | 0/394 (0%) | 11/394 (2.8%) | 246/394 (62.4%) |
| Herceptin® | 1/400 (0.3%) | 9/400 (2.3%) | 250/400 (62.5%) |
| Event | TX05 (Trastuzumab) | Herceptin® |
|---|---|---|
| Drug-induced liver injuryHepatobiliary disorders | 2/394 | 0/400 |
| Urinary Tract InfectionInfections and infestations | 2/394 | 0/400 |
| Acute Kidney InjuryRenal and urinary disorders | 0/394 | 2/400 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 1/394 | 1/400 |
| Intervertebral Disc ProtrusionMusculoskeletal and connective tissue disorders | 1/394 | 0/400 |
| Diabetic Metabolic DecompensationMetabolism and nutrition disorders | 1/394 | 0/400 |
| Vaginal HemorrhageReproductive system and breast disorders | 1/394 | 0/400 |
| ThrombophlebitisVascular disorders | 1/394 | 0/400 |
| PneumoniaInfections and infestations | 1/394 | 1/400 |
| Cardiac Failure AcuteCardiac disorders | 1/394 | 0/400 |
| Event | TX05 (Trastuzumab) | Herceptin® |
|---|---|---|
| ArthralgiaMusculoskeletal and connective tissue disorders | 50/394 | 42/400 |
| MyalgiaMusculoskeletal and connective tissue disorders | 45/394 | 39/400 |
| AstheniaGeneral disorders | 30/394 | 40/400 |
| Peripheral Sensory NeuropathyNervous system disorders | 33/394 | 30/400 |
| Neuropathy PeripheralNervous system disorders | 16/394 | 33/400 |
| NauseaGastrointestinal disorders | 27/394 | 31/400 |
| Alanine Aminotransferase IncreasedInvestigations | 27/394 | 26/400 |
| AnemiaBlood and lymphatic system disorders | 26/394 | 25/400 |
| Aspartate Aminotransferase IncreasedInvestigations | 19/394 | 12/400 |
Safety population/The modified intent-to-treat (mITT) population includes all subjects who are randomized into the study and receive at least 1 dose of TX05 or Herceptin.
| Age, Continuous(years) | TX05 (Trastuzumab) | Herceptin® | Total |
|---|---|---|---|
| Mean | 54.2 ± 11.80 | 53.4 ± 10.83 | 53.8 ± 11.32 |
| Sex: Female, Male(Participants) | TX05 (Trastuzumab) | Herceptin® | Total |
|---|---|---|---|
| Female | 394 | 400 | 794 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | TX05 (Trastuzumab) | Herceptin® | Total |
|---|---|---|---|
| Hispanic or Latino | 69 | 71 | 140 |
| Not Hispanic or Latino | 325 | 328 | 653 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | TX05 (Trastuzumab) | Herceptin® | Total |
|---|---|---|---|
| American Indian or Alaska Native | 15 | 14 | 29 |
| Asian | 64 | 72 | 136 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 |
| White | 292 | 286 | 578 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 23 | 27 | 50 |
| Hormone Receptor Status(Participants) | TX05 (Trastuzumab) | Herceptin® | Total |
|---|---|---|---|
| Positive | 253 | 254 | 507 |
| Negative | 141 | 146 | 287 |
| ECOG(Participants) | TX05 (Trastuzumab) | Herceptin® | Total |
|---|---|---|---|
| Grade 0 | 316 | 305 | 621 |
| Grade 1 | 78 | 95 | 173 |
| Tumor Stage(Participants) | TX05 (Trastuzumab) | Herceptin® | Total |
|---|---|---|---|
| IIA | 142 | 141 | 283 |
| IIB | 169 | 173 | 342 |
| IIIA | 83 | 86 | 169 |
Showing the first 100 of 146 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2018 to primary completion in Nov 2020, 28 months.
Results were first posted in Jan 2022, 1 year 1 month after primary completion.
Of 272 industry-sponsored phase 3 interventional studies under Breast Neoplasms, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 63. This study's 28 months is below that.
Counting every sponsor, half of 600 studies reached it within 59 months; a quarter within 36 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Trastuzumab
Tanvex BioPharma USA, Inc.